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Plasma ceramide levels are altered 
in low and normal birth weight men 
in response to short-term high-fat 
overfeeding
Amalie Ribel-Madsen1,2, Rasmus Ribel-Madsen2,3, Kristian Fog Nielsen1, Susanne Brix  1, 
Allan A. Vaag2 & Charlotte Brøns2
Low birth weight (LBW) individuals have an increased risk of developing insulin resistance and type 2 
diabetes compared with normal birth weight (NBW) individuals. We hypothesised that LBW individuals 
exhibit an increased fatty acid flux into lipogenesis in non-adipose tissue with a resulting accumulation 
of lipotoxic lipids, including ceramides, in the blood. Therefore, we measured fasting plasma levels 
of 27 ceramides in 18 young, healthy, LBW men and 25 NBW controls after an isocaloric control diet 
and a 5-day high-fat, high-calorie diet by HPLC-HRMS. LBW men did not show elevated plasma 
ceramide levels after the control or high-fat, high-calorie diet. An increased fatty acid oxidation rate in 
these individuals during both diets may limit ceramide synthesis and thereby compensate for a likely 
increased fatty acid load to non-adipose tissue. Interestingly, LBW and NBW men decreased d18:0–
18:1/d18:1–18:0 and d18:1–24:2/d18:2–24:1 levels and increased the d18:0–24:1a level in response to 
overfeeding. Plasma d18:0–24:1a and total ceramide levels were positively associated with the fasting 
blood glucose level and endogenous glucose production after the control diet, and the total ceramide 
level was in addition positively associated with hepatic insulin resistance. Further studies are needed to 
determine if lipotoxicity contributes to insulin resistance in LBW individuals.
Low birth weight (LBW) individuals have an increased risk of developing insulin resistance and type 2 diabetes 
later in life compared with normal birth weight (NBW) individuals1–4. Accordingly, we have shown that young, 
healthy, LBW men have higher fasting blood glucose and serum insulin levels5, display impaired hepatic insulin 
sensitivity5, and, in contrast to NBW men, develop impaired peripheral insulin sensitivity in response to 5-day 
high-fat overfeeding6. However, the metabolic mechanisms behind the type 2 diabetes susceptible phenotype in 
LBW individuals are not clear. In the present study, our primary aim was to investigate if lipotoxicity induced by 
ceramides could contribute to impaired hepatic insulin sensitivity in LBW men. Moreover, as we have shown that 
NBW men of the above mentioned study population develop impaired hepatic insulin sensitivity in response 
to 5-day high-fat overfeeding6, our secondary aim was to investigate if lipotoxicity could be part of the adverse 
events leading to this. Therefore, we studied fasting plasma ceramide levels, including their precursor dihydrocer-
amides, in the LBW and NBW men of the above study population after an isocaloric control diet and after a 5-day 
high-fat, high-calorie diet intervention.
We have previously found that young, healthy, LBW men of another study population than the present herein 
display an increased whole body and adipose tissue lipolysis7,8. This was, however, not linked to elevated plasma 
non-esterified fatty acid (NEFA) or triacylglycerol levels, suggesting that an increased uptake of fatty acids from 
the blood into tissues and/or an increased clearance or metabolism of fatty acids in adipose tissue could be in 
play. Furthermore, we have demonstrated that LBW men of the present study population have a higher adipose 
tissue miR-483-3p level, and that manipulation of this level in vitro modulates adipocyte differentiation and fatty 
acid storage capacity9. Pre-adipocytes isolated from the LBW men have lower mRNA expression levels of several 
differentiation markers, supporting a notion of an impaired pre-adipocyte maturation in LBW men10. Moreover, 
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the LBW men show an increased fatty acid oxidation rate11 and a higher fasting plasma acetylcarnitine level12, 
indicative of an increased fatty acid flux through beta-oxidation in mitochondria being non-matched by the 
acetyl-CoA flux through the tricarboxylic acid cycle. Also notably, the LBW men have higher plasma hydroxyl-/
dicarboxyl-acylcarnitine levels, including 3-hydroxy-butyrylcarnitine, suggestive of an increased hepatic fatty 
acid oxidation rate, involving omega-oxidation in the endoplasmic reticulum, and an increased ketogenesis12. 
Omega-oxidation is a minor pathway for oxidation of fatty acids under normal physiological conditions, but 
an important supplementary pathway to beta-oxidation when the intracellular NEFA levels are high13. Taken 
together, we speculated that LBW individuals might have an increased fatty acid flux into non-adipose tissue, 
including in particular the liver, and further into lipogenesis with a resulting increased ectopic fat deposition.
Ectopic fat comprises potentially lipotoxic lipids such as long-chain acyl-CoAs, ceramides, and diacylglyc-
erols14, and the extent of it has been linked to pancreatic beta-cell dysfunction and insulin resistance15,16. Also, 
individuals with type 2 diabetes have elevated plasma ceramide levels17–19. Importantly, obese individuals with 
type 2 diabetes have a higher plasma LDL-ceramide level compared with obese, insulin-sensitive individuals19, 
indicating that an increased ceramide synthesis in the liver may contribute to the development of insulin resist-
ance20. Ceramides are synthesised de novo in the endoplasmic reticulum from L-serine, palmitoyl-CoA, and 
variable acyl-CoAs or generated in salvage pathways of other sphingolipids21–23. Serine palmitoyl-transferase, 
catalysing the condensation of L-serine and palmitoyl-CoA, is the rate-limiting enzyme of ceramide synthesis, 
and an increased availability of palmitic acid enhances this synthesis24–26. Therefore, an increased uptake of fatty 
acids from the blood into non-adipose tissue is expected to increase ceramide synthesis. Ceramides are poten-
tially lipotoxic to cells in several ways25,27. Thus, these lipids inhibit the phosphorylation and thereby activation 
of Akt/protein kinase B (PKB) of the insulin signalling cascade, which is a central regulator of glucose and amino 
acid uptake, anabolic processes, and cell survival28,29. Furthermore, ceramides activate Jun and NF-KB transcrip-
tion factors and may thereby enhance inflammatory responses that may interfere with insulin signalling as well25. 
A number of studies have focused on specific actions of individual ceramides, including dihydroceramides, on 
different cellular processes22. In this regard, d18:1–16:0 ceramide has been suggested to be the principal mediator 
of diet-induced insulin resistance30,31. In the present study, we hypothesised that LBW men have higher fasting 
plasma ceramide levels, including specific ceramide species and/or total ceramide, and that such changes are 
associated with their impaired insulin sensitivity.
Results
Eighteen LBW and 25 NBW men were included in the present study. Two LBW men of the recruited participants 
failed to consume all the food provided during the 5-day high-fat, high-calorie (60 E% from fat, 50% extra calo-
ries) diet, and a NBW subject felt discomfort during the clamp after the control diet and therefore did not further 
participate in this test in the control or high-fat, high-calorie diet study part.
Clinical characteristics. LBW and NBW men displayed several differences in glucose, lipid, and pro-
tein metabolism after the isocaloric control diet and high-fat, high-calorie diet and also differential changes in 
metabolism in response to the overfeeding, as published previously5,6,11,12,32,33. Furthermore, both birth weight 
groups displayed several changes in metabolism in response to the overfeeding challenge, as also published previ-
ously6,12,33. A selection of these findings is presented in brief below to provide background of the current findings 
and in Table 1 and Supplementary Table S3.
LBW men had higher fasting blood glucose (P ≤ 0.01) and serum insulin (P ≤ 0.01) levels after the control 
diet compared with NBW men5 (Table 1). Also, both LBW and NBW men increased the fasting blood glucose 
level (P ≤ 0.05 and P ≤ 0.001, respectively) in response to overfeeding, and NBW men additionally increased the 
fasting serum insulin level (P ≤ 0.05) due to this challenge6. LBW men had a higher hepatic insulin resistance 
index (P ≤ 0.05) after the control diet compared with NBW men5, and NBW men, but not LBW men, showed an 
increase in the hepatic glucose production (P ≤ 0.01) and in the hepatic insulin resistance index (P ≤ 0.001) in 
response to overfeeding6 (Table 1). LBW and NBW men did not show a different insulin-stimulated glucose infu-
sion rate (M-value) after the control diet5 (Table 1). LBW men, however, in contrast to NBW men, decreased this 
rate (P ≤ 0.05) in reaction to overfeeding6. In terms of plasma lipid profiles, LBW men had a lower fasting plasma 
HDL-cholesterol level (P ≤ 0.01 and P ≤ 0.05, respectively) after both the control and high-fat, high-calorie diets 
compared with NBW men6 (Table 1). Furthermore, both LBW and NBW men decreased fasting plasma total 
NEFA (both P ≤ 0.001), VLDL-cholesterol (P ≤ 0.01 and P ≤ 0.05, respectively), and total triacylglycerol (P ≤ 0.01 
and P ≤ 0.05, respectively) levels and increased the HDL-cholesterol level (both P ≤ 0.01) in response to overfeed-
ing6 (Table 1). LBW and NBW men did not show differences in basal glucose or fatty acid oxidation rates after the 
control or high-fat, high-calorie diet when evaluated from the indirect calorimetry in connection with the clamp, 
and they also did not change these rates in response to overfeeding6 (Table 1). However, LBW men had higher 
fatty acid oxidation rates (P = 0.05/0.07 and P = 0.10, respectively) and a lower glucose oxidation rate (P = 0.05 
and P = 0.06, respectively) at night or during sleep during both the control and high-fat, high-calorie diets, com-
pared with NBW men, when studied during the 24-hour indirect calorimetry11,32 (Supplementary Table S3). Also, 
both LBW and NBW men increased the fatty acid oxidation rate in all four reported time intervals during the 
24-hour indirect calorimetry in reaction to overfeeding (both P < 0.0001 for the 24-hour period)12. Moreover, 
both LBW and NBW men increased the total energy expenditure in all four time intervals due to this challenge 
(P = 0.0008 and P = 0.0005, respectively, for the 24-hour period)12 (Supplementary Table S3).
Ceramide levels and their relation to other lipid levels and physiological measures. LBW 
and NBW men did not show any differences in fasting plasma ceramide levels after the control or high-fat, 
high-calorie diet intervention, but both birth weight groups changed plasma levels of several ceramide species in 
response to overfeeding (Table 2). Thus, both LBW and NBW men significantly decreased d18:0–18:1/d18:1–18:0 
www.nature.com/scientificreports/
3SCiEnTifiC REPORts |  (2018) 8:3452  | DOI:10.1038/s41598-018-21419-5
(P = 0.0004 and P < 0.0001, respectively) and d18:1–24:2/d18:2–24:1 (P = 0.0002 and P = 0.0003, respectively) 
levels and increased the d18:0–24:1a level (P = 0.0062 and P = 0.0147, respectively) in response to overfeeding. 
NBW men furthermore decreased d18:0–16:1/d18:1–16:0 (P = 0.0093), d18:1–22:1/d18:2–22:0 (P = 0.0072), and 
d18:1–23:1/d18:2–23:0 (P = 0.0129) levels and showed a tendency to decrease the d18:0–20:1/d18:1–20:0 level 
(P = 0.0511) in response to overfeeding, while LBW men showed a tendency to decrease d18:0–16:1/d18:1–16:0 
(P = 0.0553) and d18:1–22:1/d18:2–22:0 (P = 0.0850) levels and increase the d18:0–25:2/d18:1–25:1/d18:2–25:0 
level (P = 0.0649) due to this challenge.
Plasma levels of many of the detected ceramides as well as of total ceramide were positively associated with 
fasting plasma VLDL-cholesterol, LDL-cholesterol, total cholesterol, and total triacylglycerol levels after both 
the control and high-fat, high-calorie diets (Supplementary Table S4). Furthermore, d18:0–16:1/d18:1–16:0 
(P = 0.0298), d18:0–18:1/d18:1–18:0 (P = 0.0076), d18:1–22:0 (P = 0.0819), d18:0–24:1a (P = 0.0144), d18:0–
26:1/d18:1–26:0 (P = 0.0054), d18:1–24:1 (P = 0.0049), d18:1–24:2/d18:2–24:1 (P = 0.0109), and total ceramide 
(P = 0.0349) levels were or tended to be positively associated with the fasting blood glucose level after the control 
diet (Fig. 1). Among these ceramides, d18:0–18:1/d18:1–18:0 (P = 0.0192), d18:0–24:1a (P = 0.0010), d18:0–26:1/
d18:1–26:0 (P = 0.0362), and d18:1–24:2/d18:2–24:1 (P = 0.0879) levels were or tended to be positively associ-
ated with the hepatic glucose production, and d18:1–22:0 (P = 0.0205), d18:1–24:1 (P = 0.0561), and total cer-
amide (P = 0.0252) levels were or tended to be positively associated with the hepatic insulin resistance index 
(Fig. 1). Also, d18:0–16:1/d18:1–16:0 (P = 0.0263), d18:0–18:1/d18:1–18:0 (P = 0.0214), d18:1–22:0 (P = 0.0279), 
NBW
(n = 25)
LBW
(n = 18)
LBW vs. NBW
(n = 18, n = 25)
C  
(Mean ± SD)
O  
(Mean ± SD)
PNBW C  
(Mean ± SD)
 O  
(Mean ± SD)
PLBW PC PO PΔ
Anthropometry
Birth weight (g) 3901 ± 207 — — 2717 ± 268 — — ≤0.001 — —
Weight (kg) 78.4 ± 9.3 78.6 ± 9.7 n.s. 77.1 ± 11.3 77.1 ± 11.4 n.s. n.s. n.s. n.s.
Height (m) 1.83 ± 0.07 — — 1.77 ± 0.05 — — ≤0.05 — —
BMI (kg/m2) 23.3 ± 2.4 23.3 ± 2.5 n.s. 24.6 ± 3.8 24.6 ± 3.8 n.s. n.s. n.s. n.s.
Lipid profiling
P-VLDL-CHOL (mM) 0.42 ± 0.16 0.33 ± 0.16 ≤0.05 0.49 ± 0.18 0.32 ± 0.12 ≤0.01 n.s. n.s. n.s.
P-LDL-CHOL (mM) 2.51 ± 0.72 2.28 ± 0.78 ≤0.05 2.69 ± 0.76 2.57 ± 0.80 n.s. n.s. n.s. n.s.
P-HDL-CHOL (mM) 1.40 ± 0.22 1.56 ± 0.25 ≤0.01 1.19 ± 0.23 1.38 ± 0.28 ≤0.01 ≤0.01 ≤0.05 n.s.
P-CHOL (mM) 4.36 ± 0.83 4.18 ± 0.82 n.s. 4.36 ± 0.78 4.27 ± 0.79 n.s. n.s. n.s. n.s.
P-TG (mM) 0.92 ± 0.35 0.73 ± 0.35 ≤0.05 1.07 ± 0.37 0.72 ± 0.24 ≤0.01 n.s. n.s. n.s.
Clamp
Basal
  B-Glucose (mM) 4.59 ± 0.47 5.05 ± 0.40 ≤0.001 4.97 ± 0.48 5.18 ± 0.34 ≤0.05 ≤0.01 n.s. n.s.
  S-Insulin (pM) 30.2 ± 14.7 43.4 ± 29.2 ≤0.05 41.7 ± 14.6 44.7 ± 21.9 n.s. ≤0.01 n.s. n.s.
  P-NEFA (µM) 334 ± 136 205 ± 82 ≤0.001 406 ± 200 188 ± 91 ≤0.001 n.s. n.s. n.s.
  HGP (mg/kg·FFM/min) 2.21 ± 0.48 2.85 ± 0.99 ≤0.01 2.40 ± 0.50 2.48 ± 0.50 n.s. n.s. n.s. ≤0.05
  Hepatic IR (mg/kg·FFM/min ·pM) 68.7 ± 34.1 113.7 ± 61.5 ≤0.001 102.3 ± 50.8 108.7 ± 55.5 n.s. ≤0.05 n.s. ≤0.05
  GOX (mg/kg·FFM/min) 2.34 ± 0.76 2.43 ± 0.71 n.s. 1.95 ± 0.78 2.20 ± 0.56 n.s. n.s. n.s. n.s.
  FOX (mg/kg·FFM/min) 1.00 ± 0.38 1.02 ± 0.33 n.s. 1.11 ± 0.53 1.17 ± 0.33 n.s. n.s. n.s. n.s.
Insulin-stimulated
P-NEFA (µM) 9.29 ± 4.39 12.42 ± 6.43 ≤0.01 9.56 ± 5.03 14.39 ± 7.76 ≤0.01 n.s. n.s. n.s.
M-value (mg/kg·FFM/min) 13.73 ± 2.32 13.29 ± 3.32 n.s. 13.47 ± 3.14 11.89 ± 3.57 ≤0.05 n.s. n.s. n.s.
GOX (mg/kg·FFM/min) 5.18 ± 0.82 5.04 ± 0.98 n.s. 4.95 ± 0.92 4.78 ± 0.82 n.s. n.s. n.s. n.s.
FOX (mg/kg·FFM/min) 0.01 ± 0.25 0.17 ± 0.33 n.s. 0.13 ± 0.46 0.37 ± 0.35 ≤0.05 n.s. ≤0.05 n.s.
IVGTT
FPIR (pM) 1894 ± 1431 2604 ± 1793 ≤0.001 2135 ± 1034 2750 ± 1509 ≤0.01 n.s. n.s. n.s.
Hepatic DI 0.38 ± 0.63 0.25 ± 0.21 n.s. 0.21 ± 0.11 0.24 ± 0.13 n.s. n.s. n.s. n.s.
Peripheral DI 0.29 ± 0.19 0.35 ± 0.20 ≤0.05 0.33 ± 0.13 0.32 ± 0.17 n.s. n.s. n.s. n.s.
Table 1. Clinical characteristics of low (LBW) and normal birth weight (NBW) men following the control (C) 
and high-fat, high-calorie (O) diets. Data are presented as mean values ± standard deviations (SD). P-values are 
presented unadjusted for multiple comparisons, and P-values ≤ 0.05 are considered statistically significant. PNBW 
and PLBW: O vs. C diet within each birth weight group, PC and PO: LBW vs. NBW men within each diet, PΔ: LBW 
vs. NBW men on response values. P-values ≤ 0.05 are marked in bold. n.s.: Not significant. Other abbreviations: 
B: Blood, CHOL: Cholesterol, DI: Disposition index, FFM: Fat free mass, FOX: Fatty acid oxidation, FPIR: First 
phase insulin response, GOX: Glucose oxidation, HGP: Hepatic glucose production, IR: Insulin resistance, P: 
Plasma, S: Serum, TG: Triacylglycerol.
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NBW
(n = 25)
LBW
(n = 18)
LBW vs. NBW
(n = 18, n = 25)
(µM)
C
(Mean, CI)
O
(Mean, CI)
PNBW
QNBW
C
(Mean, CI)
O
(Mean, CI)
PLBW
QLBW
PC
QC
PO
QO
PΔ
QΔ
Lipid profiling
Ceramides
d18:0-16:0 0.39(0.25, 0.54)
(n = 2)
0.39
(0.38, 0.41)
(n = 8)
—
(n = 1)
—
—
(n = 0)
0.39
(0.38, 0.39)
(n = 9)
—
(n = 0)
— — —
d18:0-23:0 0.31(0.29, 0.33)
(n = 5)
0.30
(0.11, 0.50)
(n = 2)
—
(n = 0)
0.30
(0.24, 0.36)
(n = 3)
0.34
(0.24, 0.45)
(n = 3)
—
(n = 0)
— — —
d18:1-14:0 0.42(0.42, 0.42)
(n = 3)
0.41
(0.40, 0.42)
(n = 6)
—
(n = 1)
0.42
(0.37, 0.48)
(n = 3)
0.41
(0.40, 0.42)
(n = 7)
—
(n = 3)
— — —
d18:0-16:1/
d18:1-16:0
0.68
(0.65, 0.72)
(n = 25)
0.64
(0.60, 0.67)
(n = 25)
0.0093
0.0349
(n = 25)
0.68
(0.64, 0.72)
(n = 18)
0.64
(0.61, 0.68)
(n = 18)
0.0553
(n = 18)
0.9317 0.7598 0.7528
d18:0-18:1/
d18:1-18:0
0.54
(0.51, 0.58)
(n = 25)
0.47
(0.45, 0.50)
(n = 23)
<0.0001
0.0005
(n = 23)
0.55
(0.52, 0.59)
(n = 18)
0.49
(0.46, 0.52)
(n = 18)
0.0004
0.0030
(n = 18)
0.4717 0.4904 0.6504
d18:0-20:1/
d18:1-20:0
0.56
(0.52, 0.60)
(n = 25)
0.53
(0.49, 0.57)
(n = 25)
0.0511
(n = 25)
0.56
(0.51, 0.60)
(n = 18)
0.55
(0.50, 0.59)
(n = 18)
0.5866
(n = 18)
0.3612 0.5177 0.4032
d18:0-21:1/
d18:1-21:0
0.39
(0.37, 0.41)
(n = 24)
0.39
(0.37, 0.41)
(n = 22)
0.9066
(n = 21)
0.40
(0.37, 0.43)
(n = 16)
0.40
(0.37, 0.42)
(n = 18)
0.7817
(n = 16)
0.4361 0.4592 0.8432
d18:0-22:1 ——
(n = 0)
0.31
(0.29, 0.32)
(n = 7)
—
(n = 0)
—
—
(n = 0)
0.31
(0.28, 0.34)
(n = 3)
—
(n = 0)
— — —
d18:1-22:0 0.93(0.86, 1.01)
(n = 25)
0.96
(0.89, 1.04)
(n = 25)
0.3741
(n = 25)
0.93
(0.85, 1.01)
(n = 18)
0.98
(0.91, 1.06)
(n = 18)
0.1514
(n = 18)
0.8353 0.6164 0.5904
d18:0-23:1/
d18:1-23:0
1.03
(0.93, 1.13)
(n = 25)
1.11
(1.02, 1.20)
(n = 25)
0.1032
(n = 25)
1.05
(0.94, 1.15)
(n = 18)
1.12
(1.02, 1.23)
(n = 18)
0.1684
(n = 18)
0.7634 0.8162 0.9146
d18:0-24:1a 0.34(0.32, 0.37)
(n = 24)
0.39
(0.35, 0.42)
(n = 24)
0.0147
0.0368
(n = 23)
0.35
(0.32, 0.38)
(n = 18)
0.40
(0.37, 0.43)
(n = 18)
0.0062
0.0310
(n = 18)
0.7144 0.4813 0.7271
d18:0-24:1b 0.27(0.26, 0.28)
(n = 7)
0.27
(0.22, 0.33)
(n = 2)
—
(n = 2)
0.27
(0.25, 0.28)
(n = 6)
0.26
(0.14, 0.37)
(n = 2)
—
(n = 1)
— — —
d18:1-24:0 2.46(2.24, 2.69)
(n = 25)
2.50
(2.23, 2.76)
(n = 25)
0.7670
(n = 25)
2.36
(2.09, 2.63)
(n = 18)
2.60
(2.37, 2.83)
(n = 18)
0.1415
(n = 18)
0.8736 0.5577 0.5826
d18:0-25:1a 0.23(0.21, 0.25)
(n = 3)
0.24
(0.22, 0.27)
(n = 7)
—
(n = 3)
0.24
(0.14, 0.34)
(n = 2)
0.25
(0.10, 0.40)
(n = 2)
—
(n = 1)
— — —
d18:0-25:1b/
d18:1-25:0
0.83
(0.76, 0.90)
(n = 23)
0.84
(0.75, 0.93)
(n = 21)
0.4492
(n = 20)
0.76
(0.65, 0.86)
(n = 17)
0.81
(0.72, 0.89)
(n = 14)
0.3151
(n = 14)
0.1708 0.4947 0.9980
d18:0-26:1/
d18:1-26:0
0.35
(0.32, 0.38)
(n = 25)
0.35
(0.32, 0.38)
(n = 24)
0.9815
(n = 24)
0.33
(0.30, 0.36)
(n = 18)
0.35
(0.32, 0.38)
(n = 18)
0.1540
(n = 18)
0.4142 0.8835 0.2877
d18:0-16:2/
d18:1-16:1/
d18:2-16:0
0.40
(0.39, 0.41)
(n = 12)
0.40
(0.37, 0.44)
(n = 3)
—
(n = 3)
0.40
(0.39, 0.40)
(n = 8)
0.40
(0.38, 0.42)
(n = 3)
—
(n = 2)
— — —
d18:0-18:2/
d18:1-18:1/
d18:2-18:0
0.38
(0.37, 0.40)
(n = 10)
0.37
—
(n = 1)
—
(n = 1)
0.37
(0.35, 0.39)
(n = 4)
0.37
(0.36, 0.37)
(n = 3)
—
(n = 1)
— — —
d18:0-20:2/
d18:1-20:1/
d18:2-20:0
0.35
(0.33, 0.37)
(n = 6)
0.35
(0.33, 0.37)
(n = 2)
—
(n = 2)
0.36
(0.30, 0.41)
(n = 2)
0.34
—
(n = 1)
—
(n = 0)
— — —
d18:1-22:1/
d18:2-22:0
0.61
(0.55, 0.67)
(n = 25)
0.55
(0.49, 0.61)
(n = 24)
0.0072
0.0349
(n = 24)
0.60
(0.53, 0.66)
(n = 18)
0.55
(0.50, 0.60)
(n = 18)
0.0850
(n = 18)
0.7229 0.9095 0.6341
d18:1-23:1/
d18:2-23:0
0.43
(0.39, 0.47)
(n = 24)
0.39
(0.36, 0.42)
(n = 25)
0.0129
0.0368
(n = 24)
0.41
(0.37, 0.44)
(n = 16)
0.40
(0.37, 0.43)
(n = 16)
0.8063
(n = 14)
0.3331 0.3484 0.4277
d18:1-24:1 1.80(1.61, 1.98)
(n = 25)
1.67
(1.49, 1.85)
(n = 25)
0.1996
(n = 25)
1.74
(1.54, 1.95)
(n = 18)
1.68
(1.52, 1.85)
(n = 18)
0.4831
(n = 18)
0.7598 0.5826 0.6266
d18:0-25:2/
d18:1-25:1/
d18:2-25:0
0.42
(0.35, 0.48)
(n = 25)
0.46
(0.41, 0.51)
(n = 25)
0.1854
(n = 25)
0.42
(0.33, 0.50)
(n = 16)
0.44
(0.38, 0.51)
(n = 18)
0.0649
(n = 16)
0.8421 0.6268 0.9093
Continued
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d18:0–26:1/d18:1–26:0 (P = 0.0912), d18:1–24:1 (P = 0.0927), d18:1–24:2/d18:2–24:1 (P = 0.0376), and total cer-
amide (P = 0.0326) levels were or tended to be positively associated with the fatty acid oxidation rate determined 
in connection with the clamp examination after the control diet (Fig. 1).
An increase in the d18:0–25:2/d18:1–25:1/d18:2–25:0 level (P = 0.0578) in response to overfeeding tended to 
associate with an increase in the hepatic insulin resistance index (Fig. 1). Furthermore, decreases in d18:0–18:1/
d18:1–18:0 (P = 0.0607), d18:1–24:0 (P = 0.0793), d18:1–22:1/d18:2–22:0 (P = 0.0487), d18:1–24:1 (P = 0.0437), 
and total ceramide (P = 0.0336) levels due to overfeeding were or tended to be associated with a decrease in the 
insulin-stimulated glucose uptake rate (M-value) (Fig. 1).
Discussion
In contrast to expected, LBW men did not show altered fasting plasma ceramide levels after the control or 
high-fat, high-calorie diet intervention compared with NBW men. The increased fatty acid oxidation rate in the 
LBW men during both diets11,32 may limit the amount of fatty acid substrates available for de novo ceramide syn-
thesis and thereby compensate for a possible increased fatty acid load to non-adipose tissue in these individuals. 
Both LBW and NBW men decreased plasma levels of several ceramide species in response to high-fat overfeed-
ing, all of these d18:0-/d18:1- or d18:1-/d18:2- levels with the d18:1- species expected to be the dominant isomer 
in the pools, and increased the d18:0–24:1a level. Our findings of decreases in plasma levels of several ceramides 
in response to overfeeding are consistent with decreases in fasting plasma levels of several other lipid classes in 
the LBW and NBW men due to this challenge, including total NEFA, VLDL-cholesterol, total triacylglycerol, and 
total acylcarnitine levels6,12. The decreases in fasting plasma levels of several lipids, including a number of cer-
amide species, in the LBW and NBW men in response to overfeeding could very like be a result of their markedly 
increases in fatty acid oxidation rates and total energy expenditures due to this challenge12.
Several studies have reported altered plasma and/or tissue ceramide levels in mice exposed to high-fat feed-
ing34–37, and a recent study has described changes in serum ceramide levels in human subjects exposed to high-fat 
overfeeding38. Thus, sedentary women and men decrease fasting serum d18:0–18:0, d18:1–18:0, and d18:1–24:1 
levels and increase d18:0–22:0, d18:0–24:0, d18:1–22:0, d18:1–24:0, and total d18:1- ceramide levels in response 
to 28-day high-fat overfeeding (45 E% from fat, 1,250 extra kcal)38. Furthermore, these individuals increase fast-
ing serum HDL-cholesterol and total cholesterol levels in response to overfeeding, while they do not change 
LDL-cholesterol, total NEFA, and total triacylglycerol levels38. Important differences between this and the present 
overfeeding study are the duration and fat contents of the high-fat, high-calorie diet interventions. The increases 
in fatty acid oxidation rates and total energy expenditures in the LBW and NBW men in response to the 5-day 
high-fat overfeeding could be a transient, compensatory mechanism to prevent an accumulation of lipids in 
non-adipose tissue and may not persist for long-term high-fat overfeeding exposures. This hypothesis, however, 
requires further investigations. Also, both genders are examined in the reported 28-day overfeeding study and 
these individuals are somewhat older (21–65 years of age) (37 ± 2 years of age)38 than the presently examined men 
NBW
(n = 25)
LBW
(n = 18)
LBW vs. NBW
(n = 18, n = 25)
(µM)
C
(Mean, CI)
O
(Mean, CI)
PNBW
QNBW
C
(Mean, CI)
O
(Mean, CI)
PLBW
QLBW
PC
QC
PO
QO
PΔ
QΔ
d18:0-26:2/
d18:1-26:1/
d18:2-26:0
0.25
(0.23, 0.28)
(n = 15)
0.23
(0.22, 0.24)
(n = 20)
—
(n = 12)
0.23
(0.21, 0.25)
(n = 12)
0.24
(0.23, 0.26)
(n = 13)
—
(n = 10)
— — —
d18:1-24:2/
d18:2-24:1
0.87
(0.77, 0.97)
(n = 25)
0.66
(0.55, 0.76)
(n = 24)
0.0003
0.0023
(n = 24)
0.84
(0.73, 0.95)
(n = 18)
0.62
(0.52, 0.73)
(n = 18)
0.0002
0.0030
(n = 18)
0.4659 0.8498 0.9681
d18:0-26:3/
d18:1-26:2
0.27
(0.24, 0.31)
(n = 20)
0.31
(0.17, 0.45)
(n = 5)
—
(n = 5)
0.29
(0.25, 0.32)
(n = 13)
0.37
(0.32, 0.42)
(n = 7)
—
(n = 4)
— — —
d18:0-26:4b/
d18:1-26:3/
d18:2-26:2
0.15
(0.13, 0.17)
(n = 5)
0.16
(0.00, 0.32)
(n = 2)
—
(n = 0)
0.16
(0.13, 0.19)
(n = 3)
0.13
(0.08, 0.18)
(n = 3)
—
(n = 1)
— — —
Total levels
d18:0— 0.53(0.39, 0.66)
(n = 25)
0.70
(0.53, 0.87)
(n = 25)
0.0778
(n = 25)
0.52
(0.41, 0.62)
(n = 18)
0.76
(0.56, 0.97)
(n = 18)
0.0197
(n = 18)
0.9244 0.6176 0.6015
All
13.21
(11.93, 
14.49)
(n = 25)
12.39
(11.22, 
13.55)
(n = 25)
0.1549
(n = 25)
12.71
(11.30, 
14.12)
(n = 18)
12.82
(11.61, 
14.02)
(n = 18)
0.8709
(n = 18)
0.7785 0.4569 0.2853
Table 2. Plasma ceramide levels in low (LBW) and normal birth weight (NBW) men following the control (C) 
and high-fat, high-calorie (O) diets. Data are presented as mean values with 95% confidence intervals (CI). 
P-values ≤ 0.05 are presented together with Q-values, and P-values ≤ 0.05 with corresponding Q-values ≤ 0.05 
are considered statistically significant. P-values were not calculated, if more than 25% of the values within one 
of the two groups to be compared were missing. PNBW and PLBW: O vs. C diet within each birth weight group, 
PC and PO: LBW vs. NBW men within each diet, PΔ: LBW vs. NBW men on response values. P-values ≤ 0.05 
and Q-values ≤ 0.05 are marked in bold. Total d18:0− levels: d18:0–16:0, d18:0–23:0, d18:0–22:1, d18:0–24:1a, 
d18:0–24:1b, and d18:0–25:1a, Total ceramide levels: All 27 ceramide species (individual or pools).
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Figure 1. Heat-map of associations between plasma ceramide levels and physiological measures following the 
control (C) and high-fat, high-calorie (O) diets and between response values (D). Data are presented as r-values 
(red or blue colour variations for positive or negative values, respectively) and P-values (+/−: P ≤ 0.05, ++/− 
−: P ≤ 0.01, +++/−−−: P ≤ 0.001, (+)/(−): P ≤ 0.1 for positive or negative associations, respectively). r-values 
are in the range −0.4 to 0.4. P-values are presented unadjusted for multiple comparisons, and P-values ≤ 0.05 
are considered statistically significant. Regression analyses were performed on the pooled data set of LBW and 
NBW men and were adjusted for age, BMI, and birth weight group. B or I indicated in parentheses after clamp 
measures specify basal or insulin-stimulated state, respectively. Other abbreviations: See Table 1.
www.nature.com/scientificreports/
7SCiEnTifiC REPORts |  (2018) 8:3452  | DOI:10.1038/s41598-018-21419-5
(23–27 years of age) (24 ± 1 years of age). Among the studies performed in mice, several different experimental 
setups in regard to the high-fat diet intervention have been used34–37. Thus, wild-type mice fed a 16-week high-fat 
(60 E% from fat) diet have higher plasma levels of all measured ceramides, including seven d18:1- species, com-
pared with mice fed a low-fat (10 E% from fat) diet, and also higher plasma total ceramide and adipose tissue total 
ceramide levels34. In addition, mice fed an 8-week high-fat (60 E% from fat) diet have higher liver total ceramide, 
including seven d18:1- species, and total diacylglycerol contents compared with mice fed a standard chow35. 
Plasma ceramide levels were not measured in these mice35. Interestingly, adiponectin administration to the mice 
fed the 8-week high-fat diet, and in addition to leptin deficient (ob/ob) mice, rapidly normalises liver ceramide, 
but not diacylglycerol, contents, regardless of ceramide species (d18:0− or d18:1−)35. Also, adiponectin adminis-
tration to the ob/ob mice results in a reduction of the hepatic glucose production and an improvement in hepatic, 
but not skeletal muscle, insulin sensitivity35. Notably, adiponectin exerted these effects through lowering of the 
liver ceramide content via receptor-mediated enhancement of ceramidase activities35. Previously, we have found 
that both LBW and NBW men of the present study population increase the fasting plasma adiponectin level in 
response to overfeeding6. This, besides to their increases in fatty acid oxidation rates, may prevent an accumu-
lation of ceramides in the liver. Furthermore, the LBW and NBW men examined herein increase the fasting 
serum fibroblast growth factor 21 (FGF-21) level in response to the overfeeding challenge, apparently due to an 
increased FGF-21 secretion from the liver39. FGF-21 administration to mice fed a high-fat (40 E% from fat) diet, 
and in addition to ob/ob mice, increases fatty acid oxidation rates and total energy expenditures and reduces 
hepatosteatosis40. A recent study has shown that FGF-21 stimulates adiponectin secretion and reduces serum 
ceramide levels in mice fed a high-fat (60 E% from fat) diet41. Also, adiponectin-knockout mice are refractory 
to FGF-21 effects, including lowering of ceramide levels41. Therefore, it was concluded that FGF-21 depends on 
adiponectin to exert its insulin-sensitising effects41.
We furthermore showed that higher plasma levels of several ceramides as well as of total ceramide were asso-
ciated with a higher fasting blood glucose level and a higher degree of hepatic insulin resistance after the control 
diet. These findings are consistent with the observed link between liver ceramide contents and hepatic insulin 
sensitivity in the mice models used to investigate adiponectin effects35. A recent study has moreover shown that 
cultured rat hepatocytes exposed to high concentrations of palmitic acid have higher intracellular ceramide con-
centrations and are less responsive to insulin26. The latter was caused by an inhibition of the insulin-stimulated 
phosphorylation of Akt/PKB and glycogen synthase kinase26. The NBW men develop impaired hepatic insulin 
sensitivity and increase the hepatic glucose production in response to high-fat overfeeding, while the LBW men 
show impaired hepatic insulin sensitivity already after the control diet and do not reduce this sensitivity further 
in response to the overfeeding challenge5,6. Our findings of decreases in plasma levels of several ceramides in 
response to overfeeding in the NBW men do not support a possible role of ceramides in promoting hepatic insu-
lin resistance in these individuals. Nevertheless, it is remarkable that some d18:0- species, or dihydroceramides, 
were only or predominantly detected in plasma from the LBW and NBW men after the high-fat, high-calorie diet 
(Table 2). Furthermore, the LBW and NBW men solely increased the d18:0–24:1a level in response to overfeed-
ing. A higher d18:0–24:1a level was strongly significantly associated with an increased hepatic glucose production 
after the control diet. Interestingly, a newly study has reported that individuals who progress to type 2 diabe-
tes have elevated plasma levels of specific long-chain fatty acid-containing d18:0- species several years before 
disease onset42. Moreover, we found that decreases in plasma levels of several ceramides and total ceramide in 
response to overfeeding were associated with a decrease in peripheral insulin sensitivity. The LBW men, but not 
NBW men, develop impaired peripheral insulin sensitivity in response to the high-fat overfeeding challenge6. 
Several studies have reported negative correlations between skeletal muscle total ceramide contents and insulin 
sensitivity43–45. One of these studies additionally reports a positive correlation between skeletal muscle levels of 
some ceramide species and insulin sensitivity in older individuals45. Interestingly, it has been shown that circu-
lating LDL-ceramide in mice specifically targets skeletal muscle and induces insulin resistance19, emphasising the 
important role of ceramide metabolism in the liver. Here, we demonstrated that higher plasma levels of most of 
the detected ceramide species as well as of total ceramide were strongly significantly associated with higher fasting 
plasma VLDL- and LDL-cholesterol levels after both the control and high-fat, high-calorie diets. However, it is 
unknown to what extent circulating VLDL- or LDL-ceramides formed in the liver versus ceramides synthesised 
in skeletal muscle interfere with insulin signalling in this tissue.
Our study is the first to investigate plasma ceramide profiles in LBW men at risk of developing type 2 diabetes, 
compared with NBW men, and among a few studies to examine plasma ceramide profiles in human subjects 
exposed to short-term high-fat overfeeding. The ceramide profiles reported herein are moreover very detailed 
and related to measures of both hepatic and peripheral insulin sensitivity. In conclusion, LBW men did not show 
altered fasting plasma ceramide levels after the control or high-fat, high-calorie diet intervention compared with 
NBW men. We suggest that the increased fatty acid oxidation rate in the LBW men during both diets11,32 may 
limit the amount of fatty acid substrates available for lipogenesis, including de novo ceramide synthesis, and 
thereby may compensate for a likely increased fatty acid load to non-adipose tissue in these individuals. Both 
LBW and NBW men decreased plasma levels of several ceramide species in response to overfeeding. This could 
very likely be a result of their increases in fatty acid oxidation rates and total energy expenditures due to the 
overfeeding challenge12, potentially evoked by their increases in fasting serum FGF-2139 and plasma adiponectin6 
levels. Alternatively, it might be a result of a FGF-21 and adiponectin mediated activation of ceramidases in the 
liver with a following increase in the ceramide degradation. A higher plasma total ceramide level was associated 
with a higher degree of hepatic insulin resistance after the control diet. Further studies are needed to determine if 
an accumulation of potentially lipotoxic lipids in tissue and plasma is part of the adverse metabolic events leading 
to insulin resistance in LBW individuals. Also, additional investigations are required to determine possible spe-
cific roles of individual ceramides, including dihydroceramides, in interfering with insulin signalling in the liver 
and skeletal muscle.
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Methods
Ceramide analyses were performed on plasma samples from LBW and NBW men subjected to dietary 
interventions and physiological tests prior to the present study, as described in short below and in earlier 
publications5,6,11,12,32.
Study population. Forty-six young (23–27 years of age), healthy men were recruited from the Danish 
National Birth Registry according to birth weight. Among these, 20 men had a LBW (2717 ± 268 g) (≤10th per-
centile) and 26 men a NBW (3901 ± 207 g) (50–90th percentile). All men were born at term (39–41 weeks of 
gestation) in Copenhagen from 1979–1980. Also, all men were non-obese (BMI <30 kg/m2), did not perform 
strenuous physical activity >10 h/week, and did not have a family history of diabetes in two generations.
Study design. Diet interventions. All men were, in a randomised crossover study setup, standardised 
with regard to diet and physical activity and following subjected to a 3-day control diet and a 5-day high-fat, 
high-calorie diet intervention separated by a 6–8 week wash out-period. The control diet was prepared to reflect a 
habitual, weight-maintaining diet (2,819 ± 238 kcal/day) with 15, 50, and 35 E% from protein, carbohydrate, and 
fat, respectively, and the high-fat, high-calorie diet was composed to contain 50% extra calories (4,228 ± 334 kcal/
day) with 7.5, 32.5, and 60 E% from protein, carbohydrate, and fat, respectively (Supplementary Table S1). Both 
diets were provided as five daily servings, and the meals were identical from day to day. Energy requirements of 
the individual participants were calculated from a WHO equation for men <30 years of age with a low physical 
activity level46, and dietary calculations were made in Dankost Pro (The National Food Agency, Copenhagen, 
Denmark).
Clinical examinations. Study activities were performed over 3 days with the first of these days being 
placed 1 or 3 days following the start of the control and high-fat, high-calorie diet intervention, respectively. 
Anthropometry measures were recorded on day 1. An intravenous glucose tolerance test (IVGTT) and a 
hyperinsulinaemic-euglycaemic clamp were carried out in the morning on day 3 to assess insulin secretion and 
sensitivity, as described previously5,6. Furthermore, indirect calorimetry was conducted throughout 24 hours 
from day 1–2 as well as in the basal and insulin-stimulated steady-state periods of the clamp to determine sub-
strate oxidation rates and total energy expenditures, as also described previously6,11,32. Blood samples were col-
lected prior to and during the clamp.
Laboratory measurements. Ceramide analyses. Ceramide analyses were performed on EDTA-plasma 
samples collected following an overnight fast (10.00 PM–7.00 AM) and immediately prior to the clamp exami-
nation. These analyses included a semi-quantitative determination of 27 ceramide species (individual or pools), 
denoted by the sphingoid base (i.e. d18:0-, d18:1-, or d18:2-) and acyl group (e.g. −24:0) in accordance to their 
carbon chain length and number of double bonds (Table 2, Supplementary Table S2).
Aliquots of 200 µL plasma were spiked with 100 µL d18:1–16:0-2H31 internal standard (Avanti Polar Lipids, 
Alabaster, AL, USA) solution (0.4 nmol/100 µL 2:1 chloroform:methanol), and lipids were then extracted with 
1.5 mL ice-cold methanol, 3.0 ice-cold mL chloroform, and 960 µL ice-cold 0.73% sodium chloride solution 
according to the Bligh and Dyer method47. After centrifugation, the lower organic phases were transferred to 
new glass tubes, evaporated to dryness under nitrogen gas, and re-dissolved in 200 µL chloroform. Following, 
the lipid extracts were applied to n-hexane washed Strata NH2-columns (55 µm, 500 mg, 3 mL) (Phenomenex, 
Torrance, CA, USA). Cholesterolesters and triacylglycerols were first eluted with 3.0 mL 100:5:5 hexane:chloro-
form:ethylacetate, and cholesterol, diacylglycerols, and ceramides were subsequently eluted with 6.0 mL 23:1 
chloroform:methanol into separate glass tubes. Ceramide fractions were evaporated to dryness under nitrogen 
gas, re-dissolved in 50 µL chloroform and 100 µL iso-propanol, and transferred to HPLC vials.
For HPLC-HRMS analyses, 1.0 µL sample was injected into an UltiMate 3000 HPLC system (Dionex, 
Sunnyvale, CA, USA) and separated through a Kinetex C8-column (2.1 × 100 mm, 2.7 µm) (Phenomenex) at 
60 °C by elution with a water with 20 mM formic acid (A)-1:4 iso-propanol:acetonitrile (B) gradient. An elu-
ent flow rate of 0.4 mL/min was applied, and the gradient started at 35% B, increased linearly from 35–70% B 
(0.0–1.5 min) and further from 70–100% B (1.5–9.5 min), remained at 100% B (9.5–11.0 min), decreased linearly 
from 100–35% B (11.0–11.1 min), and finally remained at 35% B (11.1–13.0 min). Following, the effluent was 
introduced into a maXis HD quadrupole TOF-MS (Bruker, Bremen, Germany) equipped with an ESI ion source 
operated in positive ion mode with the collision energy alternating between 0 and 25 eV every 500 ms (BBCid 
fragmentation), thereby generating the [M+H]+-ion of the ceramides and [M+H–H2O]+-fragment ion as well 
as a fragment ion only containing the sphingoid base moiety of the ceramides. Using an aggressive dereplication 
approach48 and Bruker Target Analysis 1.3 (Bruker), ceramide species were then identified from HPLC retention 
times and accurate masses of the [M+H]+-ion (quantifier ion), [M+H–H2O]+-fragment ion (qualifier ion 1), and 
sphingoid base moiety fragment ion (qualifier ion 2) (for all ions with a m/z tolerance of ±10 ppm). This enables 
the distinction between different position isomers (e.g. d18:0–24:1 and d18:1–24:0).
A total of 90 ceramide species were searched, including ceramides with a d18:0, d18:1, or d18:2 sphingoid 
base in all possible combinations with a 14:0–26:0, 14:1–26:1, 14:2–26:2, 24:3–26:3, or 26:4 acyl group, listed in 
Supplementary Table S2 together with m/z-values of their respective [M+H]+-ions, [M+H–H2O]+-fragment 
ions, and sphingoid base moiety fragment ions. Among these, 57 ceramide species were identified in the total 
set of plasma samples. Some species were, however, only detected in a few samples and therefore not included in 
Table 2. Furthermore, the peak areas of several position isomers (e.g. d18:0–16:1 and d18:1–16:0) were combined 
in the HPLC chromatograms due to similar retention times of these isomers. These were therefore pooled. Also, a 
few ceramide species with identical molecular formulas (e.g. d18:0–24:1) were identified at two different retention 
www.nature.com/scientificreports/
9SCiEnTifiC REPORts |  (2018) 8:3452  | DOI:10.1038/s41598-018-21419-5
times, presumably corresponding to different structural isomers of the unsaturated acyl group. These isomers are 
denoted a and b, respectively. Taken together, 27 ceramide species (individual or pools) were selected for quanti-
fications and included in Table 2.
For quantifications, external standard samples, comprising a dilution row of d18:1–14:0, d18:1–24:0, d18:1–
18:1, d18:1–24:1, and d18:1–16:0-2H31 standard (Avanti Polar Lipids, Alabaster, AL, USA) solutions (1:2 chloro-
form:iso-propanol), were analysed by HPLC-HRMS parallel to the plasma samples to determine the area-mass 
relationships of these species. For all standards, this was linear within the relevant concentration ranges. 
Ceramide peak areas in the plasma samples were adjusted for the recovery of the d18:1–16:0-2H31 internal stand-
ard (79.0 ± 3.6%) and following converted to masses from the response of their respective external standard or 
an estimated response. Calculations of estimated responses were based on the assumption of an equal change 
in response per carbon atom and per double bond in the acyl group. These changes were determined from the 
responses of d18:1–14:0 compared with d18:1–24:0 and d18:1–24:0 compared with d18:1–24:1, respectively. 
d18:0-, d18:1-, and d18:2- species with identical acyl groups were assigned the same response. Also, ceramides 
that were pooled were assigned the response of the d18:1- position isomer that was expected to be the dominant 
isomer. Total d18:0-, or dihydroceramide, levels were calculated as the sum of the d18:0–16:0, d18:0–23:0, d18:0–
22:1, d18:0–24:1a, d18:0–24:1b, and d18:0–25:1a levels, and total ceramide levels were calculated as the sum of the 
levels of the 27 ceramide species (individual or pools) included in Table 2.
Ceramide analyses were performed at the Metabolomics Platform, Department of Biotechnology and 
Biomedicine, Technical University of Denmark, Kongens Lyngby, Denmark.
Ethical approval. All study procedures were in accordance with the principles of The Declaration of Helsinki 
and approved by The Regional Research Ethics Committee of Copenhagen, Denmark. Furthermore, all partic-
ipants were provided with written information on the study purpose and procedures and signed an informed 
consent prior to their participation.
Statistical analyses. Ceramide levels and their relation to other lipid levels and physiological measures. 
Ceramide data presented in Table 2, including plasma levels of individual species within each combination of 
birth weight group and diet intervention and differences in these levels between the two diets (response values) 
within each birth weight group, were evaluated for normality by Shapiro-Wilk tests with a significance level of 
0.05. Plasma levels of individual ceramide species within each diet and response values were furthermore evalu-
ated for equality of variances between the birth weight groups by F-tests with a significance level of 0.05 as well. 
Statistically significant differences in plasma ceramide levels between NBW and LBW men within each diet and 
in response values between the birth weight groups were subsequently assessed by Student’s two-tailed, unpaired 
t-tests (for normally distributed values) or Wilcoxon ranked-sum tests (for non-normally distributed values). 
Furthermore, significant differences in plasma ceramide levels between the control and high-fat, high-calorie 
diets within each birth weight group were assessed by Student’s two-tailed, paired t-tests (for normally distrib-
uted values) or Wilcoxon signed-rank tests (for non-normally distributed values). P-values from Student’s t-tests 
and Wilcoxon tests were evaluated in context with false discovery rates (Q-values) to account for multiple test-
ing within each diet or birth weight group. Q-values were calculated by the Benjamini and Hochberg method. 
P-values ≤ 0.05 with Q-values ≤ 0.05 were considered statistically significant. Data in Table 2 are presented 
as mean values with 95% confidence intervals together with the number of observations within each group. 
Moreover, P- and Q-values are indicated. Student’s t-tests and Wilcoxon tests were not performed, if more than 
25% of the values within one of the two groups to be compared were missing. Total d18:0- levels were calculated 
as the sum of the d18:0–16:0, d18:0–23:0, d18:0–22:1, d18:0–24:1a, d18:0–24:1b, and d18:0–25:1a levels, and 
total ceramide levels were calculated as the sum of the levels of all 27 ceramides (individual or pools) included in 
Table 2.
Associations between plasma ceramide levels and other lipid levels or physiological measures within each diet 
and furthermore between response values, as presented in Fig. 1 and Supplementary Table S4, were assessed from 
linear regression analyses. These analyses were performed on the pooled data set of LBW and NBW men and 
were adjusted for age, BMI, and birth weight group. P-values ≤ 0.05 were considered statistically significant. Data 
in Fig. 1 and Supplementary Table S4 are presented as Spearman correlation coefficients (r-values) and P-values.
Data availability. Plasma ceramide data generated in the present study are available from the corresponding 
author on reasonable request.
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